Literature DB >> 31463106

Multiportal subxiphoid thoracoscopic major pulmonary resections.

Karel Pfeuty1, Bernard Lenot1.   

Abstract

BACKGROUND: New subxiphoid video-assisted thoracoscopic surgery (SVATS) approaches are emerging for major pulmonary resection. The underlying concept is to reduce invasiveness and morbidity, by minimising intercostal nerve trauma, without any concession on safety and carcinologic issues. This study describes and evaluates our initial experience in multiportal SVATS, compared to conventional VATS (CVATS).
METHODS: Between June 2016 and October 2017, 75 consecutive patients underwent major pulmonary resection with an original multiportal SVATS approach developed through a single or double access under the costal arch, unsystematically associated with intercostal ports for 5-mm instruments only. We retrospectively compared results of this SVATS group (n=75) against an historic CVATS group (n=75).
RESULTS: Fifty-one lobectomies, 20 segmentectomies and 4 pneumonectomies were achieved through multiportal SVATS. Sixty-eight malignant lesions and 7 benign lesions were noted. All patients with primary lung cancer underwent R0 resection and complete lymphadenectomy, with 11% of clinical N0 upstaging. When compared, the SVATS and CVATS groups were similar in terms of demographics and pathology. No statistical differences were observed in terms of conversion (9% vs. 12%), mean operative time (157 vs. 155 min), morbidity (24% vs. 32%) and 30-day mortality (0% vs. 1.3%). The SVATS group had a significantly shorter length of drainage (median: 1 vs. 3 days, P<0.001), and a shorter postoperative length of stay (median: 2 vs. 4 days, P<0.001). Comfortable pain relief on postoperative day 1 (Numeric Rating Scale ≤3) was equally achieved (96% vs. 93%) with a significantly simplified SVATS analgesic protocol (local block and opioid-free oral analgesia) compared to the CVATS analgesic protocol (paravertebral catheter and opioid-free oral analgesia). SVATS group presented significantly less patients with persistent morphine use at day 7 (4% vs. 15%, P=0.04).
CONCLUSIONS: Multiportal SVATS is a safe, carcinologic and reproducible approach for major pulmonary resection. By avoiding intercostal strains, it enables a high compliance to opioid-free analgesic protocol, contributing to significantly shorter hospitalisation and better recovery, compared to CVATS.

Entities:  

Keywords:  Enhanced Recovery After Surgery (ERAS); Video-assisted thoracoscopic surgery (VATS); multiportal; subxiphoid

Year:  2019        PMID: 31463106      PMCID: PMC6688034          DOI: 10.21037/jtd.2019.07.21

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  22 in total

1.  Resection of anterior mediastinal masses through an infrasternal approach.

Authors:  T Kido; K Hazama; Y Inoue; Y Tanaka; T Takao
Journal:  Ann Thorac Surg       Date:  1999-01       Impact factor: 4.330

2.  Video-assisted thoracoscopic surgery (VATS) lobectomy: catastrophic intraoperative complications.

Authors:  Raja M Flores; Ugonna Ihekweazu; Joseph Dycoco; Nabil P Rizk; Valerie W Rusch; Manjit S Bains; Robert J Downey; David Finley; Prasad Adusumilli; Inderpal Sarkaria; James Huang; Bernard Park
Journal:  J Thorac Cardiovasc Surg       Date:  2011-10-19       Impact factor: 5.209

3.  Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study.

Authors:  K Wildgaard; J Ravn; L Nikolajsen; E Jakobsen; T S Jensen; H Kehlet
Journal:  Acta Anaesthesiol Scand       Date:  2010-11-15       Impact factor: 2.105

Review 4.  Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.

Authors:  Tristan D Yan; Deborah Black; Paul G Bannon; Brian C McCaughan
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

5.  Total port-access robot-assisted pulmonary lobectomy without utility thoracotomy.

Authors:  Mathew Ninan; Mark R Dylewski
Journal:  Eur J Cardiothorac Surg       Date:  2010-03-01       Impact factor: 4.191

6.  Subxiphoid single-incision thoracoscopic left upper lobectomy.

Authors:  Chia-Chuan Liu; Bing-Yen Wang; Chih-Shiun Shih; Yun-Hen Liu
Journal:  J Thorac Cardiovasc Surg       Date:  2014-08-23       Impact factor: 5.209

7.  Video-assisted approach for transxiphoid bilateral lung metastasectomy.

Authors:  T C Mineo; E Pompeo; V Ambrogi; C Pistolese
Journal:  Ann Thorac Surg       Date:  1999-06       Impact factor: 4.330

8.  Thoracoscopic pneumonectomy: an 11-year experience.

Authors:  Athar Battoo; Ariba Jahan; Zhengyu Yang; Chukwumere E Nwogu; Sai S Yendamuri; Elisabeth U Dexter; Mark W Hennon; Anthony L Picone; Todd L Demmy
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

9.  Total port-access lobectomy via a subcostal trans-diaphragmatic approach for lung cancer.

Authors:  Makoto Oda; Isao Matsumoto; Ryuichi Waseda; Go Watanabe
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-31

10.  Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  John A Howington; Matthew G Blum; Andrew C Chang; Alex A Balekian; Sudish C Murthy
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more
  2 in total

1.  Simultaneous Comparison of Subxiphoid and Intercostal Wound Pain in the Same Patients Following Thoracoscopic Surgery.

Authors:  Yu-Wei Liu; Shah-Hwa Chou; Andre Chou; Chieh-Ni Kao
Journal:  J Clin Med       Date:  2022-04-18       Impact factor: 4.964

2.  Subxifoid versus transthoracic thoracoscopic lobectomy: Results of a retrospective analysis before and after matching analysis.

Authors:  Claudio Andreetti; Valentina Peritore; Mohsen Ibrahim; Antonio Gagliardi; Giacomo Argento; Giulio Maurizi; Leonardo Teodonio; Nicola Serra; Erino Angelo Rendina; Mario Santini; Alfonso Fiorelli
Journal:  Thorac Cancer       Date:  2021-03-10       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.